Neuroblastoma screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{ZAS}}{{HL}} | {{CMG}} {{AE}}{{ZAS}}{{HL}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits. | There is insufficient [[evidence]] to recommend the routine [[Screening (medicine)|screening]] for neuroblastoma as it has no mortality benefits. | ||
==Screening== | ==Screening== | ||
* There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.<ref name="US">Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015</ref><ref>{{Cite journal | * There is insufficient [[evidence]] to recommend the routine [[Screening (medicine)|screening]] for neuroblastoma by measuring the [[Vanillyl mandelic acid|vanillylmandelic acid]] and [[homovanillic acid]] at 6 months or 1 year or [[age]], as it does not have the mortality benefits.<ref name="US">Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015</ref><ref>{{Cite journal | ||
| author = [[William G. Woods]], [[Ru-Nie Gao]], [[Jonathan J. Shuster]], [[Leslie L. Robison]], [[Mark Bernstein]], [[Sheila Weitzman]], [[Greta Bunin]], [[Isra Levy]], [[Josee Brossard]], [[Geoffrey Dougherty]], [[Mendel Tuchman]] & [[Bernard Lemieux]] | | author = [[William G. Woods]], [[Ru-Nie Gao]], [[Jonathan J. Shuster]], [[Leslie L. Robison]], [[Mark Bernstein]], [[Sheila Weitzman]], [[Greta Bunin]], [[Isra Levy]], [[Josee Brossard]], [[Geoffrey Dougherty]], [[Mendel Tuchman]] & [[Bernard Lemieux]] | ||
| title = Screening of infants and mortality due to neuroblastoma | | title = Screening of infants and mortality due to neuroblastoma | ||
Latest revision as of 18:44, 3 March 2019
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma screening On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma screening |
|
Risk calculators and risk factors for Neuroblastoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]
Overview
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.
Screening
- There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.[1][2][3][4]
References
- ↑ Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015
- ↑ William G. Woods, Ru-Nie Gao, Jonathan J. Shuster, Leslie L. Robison, Mark Bernstein, Sheila Weitzman, Greta Bunin, Isra Levy, Josee Brossard, Geoffrey Dougherty, Mendel Tuchman & Bernard Lemieux (2002). "Screening of infants and mortality due to neuroblastoma". The New England journal of medicine. 346 (14): 1041–1046. doi:10.1056/NEJMoa012387. PMID 11932470. Unknown parameter
|month=ignored (help) - ↑ Freimut H. Schilling, Claudia Spix, Frank Berthold, Rudolf Erttmann, Natalja Fehse, Barbara Hero, Gisela Klein, Johannes Sander, Kerstin Schwarz, Joern Treuner, Ulrich Zorn & Joerg Michaelis (2002). "Neuroblastoma screening at one year of age". The New England journal of medicine. 346 (14): 1047–1053. doi:10.1056/NEJMoa012277. PMID 11932471. Unknown parameter
|month=ignored (help) - ↑ "Neuroblastoma Screening (PDQ(R)): Health Professional Version". 2002. PMID 26389460.